Company
Headquarters: Beijing, China
Employees: 907
CN¥8.50 Billion
CNY as of Jan. 1, 2025
US$1.16 Billion
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $219.88 B |
| Danaher | $177.43 B |
| Siemens Healthineers AG | $59.19 B |
| Agilent Technologies, Inc. | $43.57 B |
| Lonza Group Ltd | $41.66 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Beijing Strong Biotechnologies, Inc. provides in-vitro diagnostics products and services in the People's Republic of China and internationally. It offers clinical biochemistry products, such as reagents and automatic biochemistry analyzers; coagulation products, including reagents and automated coagulation analyzers; and serology products comprising blood type test cards and automated blood grouping analyzers. The company was founded in 2001 and is headquartered in Beijing, the People's Republic of China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥1.75 B |
| EBITDA | CN¥689.8 M |
| Gross Profit TTM | CN¥1.30 B |
| Profit Margin | 30.13% |
| Operating Margin | 36.02% |
| Quarterly Revenue Growth | -0.40% |
Beijing Strong Biotechnologies, Inc. has the following listings and related stock indices.
Stock: SZSE: 300406 wb_incandescent